Company news
Imunon, Inc. (NASDAQ:IMNN) news
Imunon, Inc. news releases on 6ix. Latest, Feb 29, 2024: Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus…
Press releases — page 3
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
February 28, 2024
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
February 26, 2024
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
February 21, 2024
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2023
IMUNON’s VP of R&D to Present at the Vaccines Summit-2023
November 13, 2023
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 13, 2023
IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
November 6, 2023
IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress
October 22, 2023
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations
October 18, 2023
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
October 17, 2023
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
October 5, 2023
IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer
September 27, 2023
IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies
September 25, 2023
IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
September 12, 2023
IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET
September 6, 2023
IMUNON to Participate in the H.C. Wainwright Global Investment Conference
September 4, 2023
IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus
August 23, 2023
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
August 13, 2023
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
August 9, 2023
Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv
August 6, 2023
IMUNON Unveils New Manufacturing Capabilities at Huntsville’s HudsonAlpha Biotech Campus
June 26, 2023
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
June 25, 2023
IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells – Gordon Research Conference
May 29, 2023
IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023
May 3, 2023
IMUNON Reports 2022 Financial Results and Provides Business Update
March 29, 2023
IMUNON Announces Abstract Accepted for Presentation at the American Association for Cancer Research Annual Meeting
March 14, 2023
IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer
February 26, 2023
IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses
January 11, 2023
IMUNON Enters into Collaborative Research Agreement with The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform
January 4, 2023
IMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
December 13, 2022
IMUNON Announces Strategic Investment in Transomic Technologies
November 16, 2022
IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update
November 13, 2022
IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System
November 9, 2022
Imunon Appoints James E. Dentzer to its Board of Directors
October 2, 2022